An observational study in HIV Infections and AIDS, sponsored by National Center for Global Health and Medicine, Japan. Completed at 1 site in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-25.
Sponsored by National Center for Global Health and Medicine, Japan · Observational
This study is to investigate the safety of maraviroc by examining whether there is bone metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone mineral density and markers for bone formation, desorption and chemokine.
An observational study to investigate the safety of maraviroc by examining whether there is bone metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone mineral density and markers for bone formation, desorption and chemokine.
4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.
This study's enrollment of 16 is below the median of 200 across 713 observational studies indexed under HIV Infections.
Browse HIV Infections studies →National Center for Global Health and Medicine, Japan is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Treatment group: primary care clinic, Non-treatment group: primary care clinic and community sample
Inclusion Criteria: Outpatients or inpatients that are treated for HIV infection at AIDS Clinical Center of National Center for Global Health and Medicine who meet all criteria following:
Exclusion Criteria: Cases applicable to ANY condition of the following:
Those whose take maraviroc as a part of their HIV treatment
Drug: Maraviroc
Those who do not take maraviroc
Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
Also known as: Selzentry, or Celsentri
Evaluation of maraviroc's effect to bone metabolism and bone mineral density
Follow up HIV infected patients who take maraviroc for their bone mineral density by DEXA and for following blood/urine markers of bone metabolism and chemokine for 72 weeks: * Bone and chemokine markers (DPD, NTX, CTX, TRACP, BAP, osteocalcin, MIP-1alpha, MIP-1beta and RANTES) * Dual-energy X-ray absorptiometry
Time frame: 78 weeks
Duration of the treatment efficacy
Evaluate overall HIV management status over time with: * Other infections: HBV, HCV, RPR, TPHA * HIV treatment markers: CD4, CD8, CD4/CD8, HIV-RNA * HAART regimens and start dates * Other medications: antibiotics, anticoagulants, antiplatelets, NSAID, steroids * Past medical history * HIV risk behaviors, age, sex
Time frame: 72 weeks
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Center for Global Health and Medicine, Japan